

PRIOR AUTHORIZATION REQUEST

<u>llumya</u>

Patient Informati	on:				
Name:					
Member ID:					
Address:					
City, State, Zip:					
Date of Birth:					
Prescriber Inform	nation:				
Name:					
NPI:					
Phone Number:					
Fax Number					
Address:					
City, State, Zip:					
Requested Medic	cation				
Rx Name:					
Rx Strength					
Rx Quantity:					
Rx Frequency:					
Rx Route of					
Administration:					
Diagnosis and ICD Code:					
prescribed a medicat quantities can be pro Upon receipt of the	ion for your vided. Plea complete	efit requires that we review certain requests for coverage with the prescriber. You have a patient that requires Prior Authorization before benefit coverage or coverage of additional use complete the following questions then fax this form to the toll-free number listed belowed form, prescription benefit coverage will be determined based on the plan's rules that supporting clinical documentation is required for ALL PA			
synthetic condition? [] Biologic Kevzara, Renflexis, IV]) (If che [] Targete (If checke	 Will the requested medication be used in combination with a biologic or with a targeted synthetic disease-modifying antirheumatic drug (DMARD) used for an inflammatory condition? [] Biologic DMARD (such as Cimzia, Cosentyx, Enbrel, Erelzi, Humira, Amjevita, Cyltezo, Kevzara, Tremfya, Actemra [IV or SC], Kineret, Rituxan, Truxima, Remicade, Inflectra, Renflexis, Siliq, Skyrizi, Simponi [SC or Aria], Stelara [IV or SC], Taltz, or Orencia [SC or IV]) (If checked, no further questions) [] Targeted synthetic DMARD (such as Olumiant, Otezla, Rinvoq, Xeljanz, or Xeljanz XR) (If checked, no further questions) [] Conventional synthetic DMARD (such as methotrexate, leflunomide, sulfasalazine, hydroxychloroquine) (If checked, go to 2) 				

If you have any questions, call: 1-888-258-8250

PRIOR AUTHORIZATION REQUEST

	[] No, the requested medication will NOT be used in combination with another BIOLOGIC or Targeted Synthetic disease-modifying antirheumatic drug (DMARD) (If checked, go to 2)		
2	What is the diagnosis or indication? [] Plaque psoriasis (If checked, go to 3)		
	[] Other (If checked, no further questions)		
3	Is the patient currently receiving the requested medication? [If yes, skip to question 9.]	Yes	No
4	Is the patient greater than or equal to 18 years of age? [If no, no further questions.]	Yes	No
5	Has the patient tried at least one traditional systemic agent for psoriasis for at least 3 months, unless intolerant? [NOTE: Examples of one traditional systemic agent include methotrexate (MTX), cyclosporine, acitretin tablets, or psoralen plus ultraviolet A light (PUVA).] [If yes, skip to question 8.]	Yes	No
6	Has the patient already had a 3-month trial or previous intolerance to at least one biologic? [NOTE: Examples include an etanercept product (Enbrel, Erelzi), Cosentyx (secukinumab SC injection), an adalimumab product (Humira), Cimzia (certolizumab pegol SC injection), an infliximab product (for example, Remicade, Inflectra, Renflexis), Siliq (brodalumab SC injection), Skyrizi (risankizumab SC injection), Stelara (ustekinumab SC injection), Taltz (ixekizumab SC injection), or Tremfya (guselkumab SC injection).] [If yes, skip to question 8.]	Yes	No
7	Does the patient have a contraindication to methotrexate, as determined by the prescriber? [If no, no further questions.]	Yes	No
8	Is the requested medication being prescribed by or in consultation with a dermatologist? [No further questions.]	Yes	No
9	Has the patient had a response, as determined by the prescriber? [NOTE: The patient may not have a full response, but there should have been a recent or past response.]	Yes	No

Please document the diagnoses, symptoms, and/or any other information important to this review:



PRIOR AUTHORIZATION REQUEST

SECTION B: Physician Signature

PHYSICIAN SIGNATURE

DATE

FAX COMPLETED FORM TO: 1-833-896-0656

Disclaimer: An authorization is not a guarantee of payment. Member must be eligible at the time services are rendered. Services must be a covered Health Plan Benefit and medically necessary with prior authorization as per Plan policy and procedures.

Confidentiality: The information contained in this transmission is confidential and may be protected under the Health Insurance Portability and Accountability Act of 1996. If you are not the intended recipient any use, distribution, or copying is strictly prohibited. If you have received this facsimile in error, please notify us immediately and destroy this document.